Last reviewed · How we verify
OTX-DED
At a glance
| Generic name | OTX-DED |
|---|---|
| Sponsor | Ocular Therapeutix, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- OTX-DED for the Short-term Treatment of the Symptoms of Dry Eye Disease (DED) (PHASE2)
- Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI in Subjects With Dry Eye Disease. (PHASE1, PHASE2)
- To Assess the Efficacy and Safety of OTX-DED for the Short-term Treatment of Signs and Symptoms of Dry Eye Disease (PHASE2)
- The DEPOT Study (Dry Eye Prescription Options for Therapy) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OTX-DED CI brief — competitive landscape report
- OTX-DED updates RSS · CI watch RSS
- Ocular Therapeutix, Inc. portfolio CI